“Bimekizumab Long-Term Efficacy in Patients With Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s433. https://doi.org/10.25251/skin.8.supp.433.